PL2726880T3 - Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty - Google Patents
Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostatyInfo
- Publication number
- PL2726880T3 PL2726880T3 PL12807837T PL12807837T PL2726880T3 PL 2726880 T3 PL2726880 T3 PL 2726880T3 PL 12807837 T PL12807837 T PL 12807837T PL 12807837 T PL12807837 T PL 12807837T PL 2726880 T3 PL2726880 T3 PL 2726880T3
- Authority
- PL
- Poland
- Prior art keywords
- prostate cancer
- prognosis
- determining
- treatment
- cancer patients
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 2
- 238000000034 method Methods 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1150619 | 2011-07-01 | ||
| PCT/SE2012/050738 WO2013006129A1 (en) | 2011-07-01 | 2012-06-28 | Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients |
| EP12807837.5A EP2726880B1 (en) | 2011-07-01 | 2012-06-28 | Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2726880T3 true PL2726880T3 (pl) | 2019-09-30 |
Family
ID=47437285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12807837T PL2726880T3 (pl) | 2011-07-01 | 2012-06-28 | Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9278119B2 (pl) |
| EP (1) | EP2726880B1 (pl) |
| DK (1) | DK2726880T3 (pl) |
| ES (1) | ES2735540T3 (pl) |
| HU (1) | HUE045368T2 (pl) |
| PL (1) | PL2726880T3 (pl) |
| TR (1) | TR201910508T4 (pl) |
| WO (1) | WO2013006129A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2796973T3 (es) * | 2014-12-10 | 2020-11-30 | Hyperstem Sa | Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales |
| CN111417403B (zh) * | 2017-10-25 | 2024-06-04 | 温特研究公司 | Wnt5a肽在减少癌症干细胞中的作用 |
| WO2020053200A1 (en) * | 2018-09-10 | 2020-03-19 | Wntresearch Ab | Peptides for use in treatment of psoriasis |
| CA3137093A1 (en) * | 2019-04-16 | 2020-10-22 | Wntresearch Ab | Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601363B1 (fr) | 1986-07-08 | 1988-10-21 | Synthelabo | (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique. |
| WO1998023730A1 (en) * | 1996-11-27 | 1998-06-04 | The Penn State Research Foundation | Compounds and methods for treating cancer |
| WO2000031261A2 (en) | 1998-11-25 | 2000-06-02 | Cadus Pharmaceutical Corporation | Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor |
| EP1033405A3 (en) | 1999-02-25 | 2001-08-01 | Ceres Incorporated | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby |
| EP1226172A1 (en) | 1999-11-05 | 2002-07-31 | Forskarpatent i Syd AB | Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis |
| JP2003516390A (ja) | 1999-12-07 | 2003-05-13 | セラヴァンス インコーポレーテッド | ムスカリンレセプターアンタゴニスト活性を有するカルバメート誘導体 |
| US7247426B2 (en) | 2001-08-02 | 2007-07-24 | Agilent Technologies, Inc. | Classifying cancers |
| AU2003295328A1 (en) | 2002-10-02 | 2004-04-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| DK2384763T3 (en) | 2005-05-30 | 2015-07-20 | Wntres Ab | Peptide ligand for disrupting cancer cell migration |
| EP2280994A4 (en) * | 2008-04-30 | 2011-05-25 | Wntres Ab | RESTORATION OF ESTROGEN RECEPTOR ACTIVITY |
| ES2527454T3 (es) | 2008-08-13 | 2015-01-23 | Wntresearch Ab | El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico |
| WO2012109540A1 (en) * | 2011-02-10 | 2012-08-16 | Fox Chase Cancer Center | Methods for inducing epithelial cancer cell senescence |
-
2012
- 2012-06-28 PL PL12807837T patent/PL2726880T3/pl unknown
- 2012-06-28 US US14/128,064 patent/US9278119B2/en active Active
- 2012-06-28 WO PCT/SE2012/050738 patent/WO2013006129A1/en not_active Ceased
- 2012-06-28 ES ES12807837T patent/ES2735540T3/es active Active
- 2012-06-28 DK DK12807837.5T patent/DK2726880T3/da active
- 2012-06-28 TR TR2019/10508T patent/TR201910508T4/tr unknown
- 2012-06-28 EP EP12807837.5A patent/EP2726880B1/en active Active
- 2012-06-28 HU HUE12807837A patent/HUE045368T2/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2726880A4 (en) | 2015-03-04 |
| WO2013006129A1 (en) | 2013-01-10 |
| DK2726880T3 (da) | 2019-07-15 |
| US9278119B2 (en) | 2016-03-08 |
| EP2726880A1 (en) | 2014-05-07 |
| TR201910508T4 (tr) | 2019-08-21 |
| EP2726880B1 (en) | 2019-04-17 |
| US20140206623A1 (en) | 2014-07-24 |
| ES2735540T3 (es) | 2019-12-19 |
| HUE045368T2 (hu) | 2019-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276362A (en) | Cancer treatment methods | |
| IL233709A (en) | A method to predict the likelihood of clinical outcome for a patient with prostate cancer | |
| PT2619576T (pt) | Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro | |
| IL237558A0 (en) | Methods for treating locally advanced breast cancer | |
| IL223189A0 (en) | Methods of treatment of pancreatic cancer | |
| ZA201308111B (en) | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor | |
| EP2675485A4 (en) | ANTI-MUCIN ANTIBODY FOR THE EARLY RECOGNITION AND TREATMENT OF PANCREATIC CANCER | |
| IL220788A (en) | Factors associated with cancer treatment and method of preparation | |
| EP2751267A4 (en) | METHOD FOR THE TREATMENT OF BREAST CANCER | |
| ZA201205004B (en) | Methods for treating pancreatic cancer | |
| EP2643001A4 (en) | METHOD OF TREATING CANCER | |
| IL232493A0 (en) | A method for quantifying cancer treatment | |
| ZA201304225B (en) | Methods of treating cancer | |
| SI2742356T1 (sl) | Prediktorji pri zdravljenju raka | |
| IL228917A0 (en) | Methods for treating solid tumors | |
| EP2640390A4 (en) | METHODS OF TREATING CANCER | |
| SG11201402115TA (en) | Methods for diagnosis and/or prognosis of gynecological cancer | |
| ZA201306807B (en) | Anti-alpha-v integrin antibody for the treatment of prostate cancer | |
| EP2593111A4 (en) | NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | |
| PL2726880T3 (pl) | Leczenie nowotworu prostaty i sposób określania prognozy dla pacjentów z nowotworem prostaty | |
| EP2709730A4 (en) | TREATMENT AND PROGNOSIS OF CANCER | |
| EP2932273A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | |
| EP2560639A4 (en) | METHOD FOR THE TREATMENT OF PROSTATE CANCER | |
| EP2721410A4 (en) | BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF EPITHELIAL CANCER | |
| ZA201208905B (en) | Cancer therapy method |